Metformin, a drug widely used to treat type 2 diabetes mellitus, has been shown to activate AMPK in the liver, thereby reducing gluconeogenesis and enhancing insulin sensitivity [23]. This evidence concerns the gene PRKAA2 and diabetes mellitus.